European Journal of Cancer
Volume 46, Issue 16 , Pages 2926-2935 , November 2010

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

  • Manfred Johannsen

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author: Tel.: +49 30 450615163; fax: +49 30 450515915.
    • ,
  • Gianluca Spitaleri

      Affiliations

    • Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    • These authors contributed equally to this work.
    • ,
  • Giuseppe Curigliano

      Affiliations

    • Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    • ,
  • Jan Roigas

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Steffen Weikert

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Carsten Kempkensteffen

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Andreas Roemer

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Christian Kloeters

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Patrik Rogalla

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Gabriele Pecher

      Affiliations

    • Department of Oncology and Hematology, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    • ,
  • Kurt Miller

      Affiliations

    • Department of Urology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Alexander Berndt

      Affiliations

    • Institute of Pathology, University Hospital Jena, Bachstraße 18, 07743 Jena, Germany
    • ,
  • Hartwig Kosmehl

      Affiliations

    • Institute of Pathology, HELIOS-Klinikum, Nordhäuser Str. 74, 99089 Erfurt, Germany
    • ,
  • Eveline Trachsel

      Affiliations

    • Philochem AG, Industriestrasse 30, 8112 Otelfingen, Switzerland
    • ,
  • Manuela Kaspar

      Affiliations

    • Philochem AG, Industriestrasse 30, 8112 Otelfingen, Switzerland
    • ,
  • Valeria Lovato

      Affiliations

    • Philochem AG, Industriestrasse 30, 8112 Otelfingen, Switzerland
    • ,
  • Reinerio González-Iglesias

      Affiliations

    • Philogen SpA, La Lizza 7,53100 Siena, Italy
    • ,
  • Leonardo Giovannoni

      Affiliations

    • Philogen SpA, La Lizza 7,53100 Siena, Italy
    • ,
  • Hans D. Menssen

      Affiliations

    • Bayer Schering Pharma AG, Müllerstrasse, 13353 Berlin, Germany
    • ,
  • Dario Neri

      Affiliations

    • Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Wolfgang-Pauli-Strasse 10, CH-8093 Zurich, Switzerland
    • Corresponding Author InformationCorresponding author: Tel.: +41 44 633 74 01; fax: +41 44 633 13 58.
    • ,
  • Filippo de Braud

      Affiliations

    • Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

Received 26 May 2010 ,Revised 19 July 2010 ,Accepted 22 July 2010.

References 

  1. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5:147–159
  2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–357
  3. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436–446
  4. Reisfeld RA, Gillies SD. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy. J Clin Lab Anal. 1996;10:160–166
  5. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 1999;59:347–352
  6. Zardi L, Carnemolla B, Siri A, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. Embo J. 1987;6:2337–2342
  7. Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood. 2002;99:1659–1665
  8. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res. 2005;11:7053s–7063s
  9. Tijink BM, Neri D, Leemans CR, et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127–1135
  10. Tarli L, Balza E, Viti F, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood. 1999;94:192–198
  11. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102:75–85
  12. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571–579
  13. Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113:2265–2274
  14. Schliemann C, Palumbo A, Zuberbuhler K, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009;113:2275–2283
  15. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets. 2005;9:491–500
  16. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293–301
  17. 17.NCI-CTCAE version 3.0. Common terminology criteria for adverse events v3.0 (CTCAE). Publication date August 9, 2006. <http://www.cancer.gov/forms/CTCAEv3.pdf> [accessed 14.07.08].
  18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  19. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769–21776
  20. Wolfgang GH, McCabe RD, Johnson DE. Toxicity of subcutaneously administered recombinant human interleukin-2 in rats. Toxicol Sci. 1998;42:57–63
  21. Anderson TD, Hayes TJ, Powers GD, Gately MK, Tudor R, Rushton A. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int Rev Exp Pathol 1993;34(Pt A):57–77.
  22. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study. J Clin Oncol. 2000;18:4077–4085
  23. Epstein AL, Khawli LA, Hornick JL, Taylor CR. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res. 1995;55:2673–2680
  24. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 2007;356:125–134
  25. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280–1289
  26. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456
  27. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med. 2007;356:115–124
  28. Johannsen M, Florcken A, Bex A, et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol. 2009;55:1430–1438
  29. Stadler WM. Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009;27:3573–3574

☆ ClinicalTrials.gov Identifier: NCT01058538.

PII: S0959-8049(10)00728-8

doi: 10.1016/j.ejca.2010.07.033

European Journal of Cancer
Volume 46, Issue 16 , Pages 2926-2935 , November 2010

Article Tools

* Image Usage & Resolution